News

Almost like clockwork, Halloween ended, stores started setting up for the all-important holiday shopping season, and the stock market started what could potentially end up as one heck of an early

Almost like clockwork, Halloween ended, stores started setting up for the all-important holiday shopping season, and the stock market started what could potentially end up as one heck of an early

Merck (NYSE: MRK) and Bristol Myers Squibb (NYSE: BMY) are both eyeing the same pie, and they're both serious about getting a big slice. But it isn't a hot market for drugs to treat a single disease

You've probably heard all the old expressions about acting too quickly. "Haste makes waste" and "Look before you leap" are two that readily come to mind. However, there's also danger in waiting too

A lot can happen in just a few years, and Novavax (NASDAQ: NVAX) is the proof of that. Three years ago, the company was rushing toward the coronavirus vaccine finish line -- and the shares were

A disappointing quarter combined with a set of analyst price target cuts -- and even a recommendation downgrade -- made Coherus BioSciences (NASDAQ: CHRS) a stock to avoid this week. As of

It's been a rough year for the biotech industry, which as a whole has substantially lagged the broader market. Just look at the performance of the SPDR S&P Biotech ETF, an industry benchmark. What's

It's been a rough year for the biotech industry, which as a whole has substantially lagged the broader market. Just look at the performance of the SPDR S&P Biotech ETF, an industry benchmark. What's

It's been a rough year for the biotech industry, which as a whole has substantially lagged the broader market. Just look at the performance of the SPDR S&P Biotech ETF, an industry benchmark. What's

The average stock in the S&P 500 has a dividend that only yields 1.6%. However, investors can secure much higher yields than that without taking on much extra risk. If you've got $5,000 that you can

The average stock in the S&P 500 has a dividend that only yields 1.6%. However, investors can secure much higher yields than that without taking on much extra risk. If you've got $5,000 that you can

It's a no-brainer to invest in businesses that are making headway in the growth markets of the future. In biopharma, therapies to treat or prevent Alzheimer's disease constitute one such growth

It's a no-brainer to invest in businesses that are making headway in the growth markets of the future. In biopharma, therapies to treat or prevent Alzheimer's disease constitute one such growth

It's a no-brainer to invest in businesses that are making headway in the growth markets of the future. In biopharma, therapies to treat or prevent Alzheimer's disease constitute one such growth

For the past couple of years, investors looked ahead to one particular thing with dread: AbbVie's (NYSE: ABBV) blockbuster immunology drug facing competition. After all, at its peak, Humira brought

Last year, the Federal Reserve began hiking interest rates in an effort to slow down the economy. Today, interest rates are at their highest levels since the early 2000s. For many businesses, an

Investing in biotech stocks is risky. And one of the more volatile ones of late is Sarepta Therapeutics (NASDAQ: SRPT). Shares of the company crashed last week after it released results from phase 3

Biotech giant Regeneron (NASDAQ: REGN) and streaming specialist Roku (NASDAQ: ROKU) have been solid performers for most of the year, but both stocks recently jumped following their third-quarter

Biotech giant Regeneron (NASDAQ: REGN) and streaming specialist Roku (NASDAQ: ROKU) have been solid performers for most of the year, but both stocks recently jumped following their third-quarter

Biotech giant Regeneron (NASDAQ: REGN) and streaming specialist Roku (NASDAQ: ROKU) have been solid performers for most of the year, but both stocks recently jumped following their third-quarter

Vertex Pharmaceuticals (NASDAQ: VRTX) generates billions of dollars in annual revenues from its treatments for the rare disease cystic fibrosis. And Vertex should continue to dominate in cystic

Vertex Pharmaceuticals (NASDAQ: VRTX) generates billions of dollars in annual revenues from its treatments for the rare disease cystic fibrosis. And Vertex should continue to dominate in cystic

Vertex Pharmaceuticals (NASDAQ: VRTX) generates billions of dollars in annual revenues from its treatments for the rare disease cystic fibrosis. And Vertex should continue to dominate in cystic